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Identity 
Other names: Metaphyseal chondrodysplasia, 
McKusick type 
Inheritance: Autosomal rezessive. 
Clinics 
Note: CHH was first described in the Amish, an 
isolated religious group in the USA by Victor 
McKusick in 1965. It is a multi-systemic disorder 
characterized by short stature, blond fine sparse hair,
but this may be quite variable, and defective cellular 
immunity predominantly affecting T-cell mediated 
responses. Patients may have severe combined 
immunodeficiency, requiring bone marrow 
transplantation or they may be asymptomatic. 
Gastrointestinal dysfunctions are frequently observed 
such as mal-absorption or Hirschsprung¹s disease. 
The incidence of CHH in the Amish is 1.5 in 1,000 
births, whereas in Finland it is 1 in 18,000 to 23,000 
live births. 
Phenotype and clinics 
The metaphyses of tubular bones are widened, 
scalloped and irregularly sclerotic. Delayed ossification 
and trabeculation of the long bones are also 
characteristic findings on X-rays. All long bones are 
affected. The relative length of the humerus, ulna, 
radius, tibia and fibula decreases rapidly in early 
childhood and again at puberty. Relatively short and 
broad phalanges of the hands are observed. 
Neoplastic risk 
A predisposition to certain cancers primarily 
lymphomas has been reported. 
Treatment 
- Disproportionate short stature: Treatment with growth 
hormone is likely not beneficial in children with CHH. 
Surgical bone lengthening is occasionally considere. 
- Orthopedic problems: The lumbar lordosis and 
ligamentous laxity can cause joint pains of the lower 
spine, the knees and ankles. 
- Immunodeficiency: The cellular immunity may be 
defective whereas the humoral immunity is usually 
intact. However, there are a few cases that have 
combined immune deficiency. 
- Vaccination: immunization with live vaccines is 
contraindicated in patients with impaired cellular 
immunity. 
- Anemia: Patients with severe anemia (5% of CHH 
patients) require repeated transfusions. A few cases 
might need lifelong transfusions and/or bone marrow 
transplantation. 
- Gastrointestinal dysfunction: This can present with 
signs of malabsorption, diarrhea, celiac disease, and 
failure to thrive. This requires symptomatic treatment. 
It also may present as Hirschsprung¹s disease that can 
be surgically corrected. 
- Malignancies: Patients should be monitored closely, 
since they have a higher risk of developing lymphomas 
and leukemias. 
Prognosis 
Adult height ranges between 111 and 151 cm in males 
and between 104 and 137 cm in females. No more than 
20% of CHH patients exhibit recurrent and severe 
infections. These patients show evidence of immune 
deficiency in vivo and in vitro. 
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Genes involved and Proteins 
Note: CHH is mainly caused by mutations in the 
RMRP gene, but a Uniparental Disomy of 9p13 has 
been reported as well in one CHH patient. 





RMRP is the RNA component of the RNase MRP 
protein complex. It functions as an RNA and is not 
translated into a protein. 
 
 
The RMRP gene is an intronless gene, that is 267 bp long 
(blue). The promoter region contains a SP1 binding site 
(violet), an octamer (olive green), a proximal sequence 
element (PSE) (turquoise) and a TATA box (red). 
Transcription: In vitro analysis of the RMRP promoter 
revealed that the four described promoter elements are 
sufficient for RMRP transcription. It is transcribed by 
the DNA dependent RNA polymerase III and is 
encoded in the nucleolus. The complex is localized 
primarily in the nucleolus and to a lesser extend in the 
mitochondria. Studies in yeast revealed multiple 
functions of this protein complex. RNase MRP is 
involved in mitochondrial DNA replication by cleaving 
the RNA primer starting mitochondrial replication ad 
is also involved in the RNA primer formation itself. In 
addition it plays a role in cell cycle progression at the 
end of mitosis. RNase MRP cleaves the 5’ UTR of the 
CLB2 gene thus causing a rapid CLB2 degradation, 
which leads to a cell cycle progression. If CLB2 is not 
cleaved cell cycle will be arrest. The best understood 
function is its processing of pre-ribosomal RNAs. It 
cleaves the pre-ribosomal RNA at the A3 site thus 
helping in the maturation of the short and active form 
of the 5.8S rRNA. 
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Protein 
Expression: Strong ubiquitous expression in mouse 
embryos (E9.5 to E18.5 have been tested) and in adult
animals. In bone Rmrp is more strongly expressed in 
hypertrophic chondrocytes and pericondrium than in 
the zone of proliferating chondrocytes. There is alo 
very strong expression in the epiphysis. 
In Xenopus laevis oocytes RMRP is stronger expressed 
in developmental stages with a higher content of 
mitochondria. 
Function:  The RNase MRP complex is highly 
conserved among a variety of different species (human, 
mouse, rat, cow, frog, yeast and plants). 
Homology 
The functional analysis of the RNase MRP 
endoribonuclease is complicated by the fact, that eight 
proteins are shared by a related ribonucleoprotein 
complex, called RNase P. RNase P is also a 
ribonucleprotein endoribonuclease and is mainly 




The most frequently found mutation among CHH 
patients is a 70 A to G transition mutation with an
ancient founder origin established in Finland, a country 
where the disorder is uncommonly frequent. In fact it is 
the only mutation found in Amish CHH patients. 
Over 93 different mutations have been described in 
CHH patients. These include promoter duplications, 
triplications and insertions exclusively between the 
TATA box and the transcription start site. These 
mutations decrease the RMRP transcription efficiency. 
Single base pair substitutions are spread out over the 
entire RMRP transcript. Also small deletions of and 
insertions in the transcribed region of the gene have 
been observed as well. These mutations might 
influence the secondary structure of the RNA, the 
binding of the proteins to the RNA or the RNA 
stability. 
In addition many polymorphisms and rare sequence 
variants have been observed. This is remarkable 
considering the very small size of the RMRP gene. 
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To be noted 
So far no complete deletion of the entire RMRP gene 
has been observed. This suggests that complete loss of 
RMRP function might be incompatible with life. This 
is also supported by the fact that the knock out in yeast 
is lethal. 
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